State Street Corporation filed a Schedule 13G with the SEC on November 9, 2026, disclosing beneficial ownership of 30,001,137 shares of Recursion Pharmaceuticals Inc. common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: State Street Corporation reported beneficial ownership of 30,001,137 shares of Recursion Pharmaceuticals common stock.
  • Percent of class: The reported stake represents 5.6% of the outstanding class of common stock.
  • Shared voting power: State Street disclosed shared power to vote or direct the vote for 28,700,743 shares, with sole voting power of zero.
  • Shared dispositive power: The filing reported shared power to dispose of 30,001,137 shares, with sole dispositive power of zero.
  • Subsidiaries involved: The acquiring entities listed include SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, State Street Global Advisors Limited, State Street Global Advisors Trust Company, and State Street Global Advisors, Ltd., each classified as an investment adviser.
  • Triggering event date: The date of the event requiring this filing was reported as September 30, 2026.

State Street Corporation Reports Beneficial Ownership Position in Recursion Pharmaceuticals

State Street Corporation, a holding company organized in Massachusetts with its principal business office at One Congress Street, Suite 1, Boston, MA 02114, filed a Schedule 13G disclosing its beneficial ownership position in Recursion Pharmaceuticals Inc. (NASDAQ:RXRX), whose principal executive offices are located at 41 South Rio Grande Street, Salt Lake City, Utah 84101. The filing was signed by Alok Maheshwary, Senior Vice President, on November 9, 2026, with the triggering event dated September 30, 2026.

According to the filing, State Street reported aggregate beneficial ownership of 30,001,137 shares of common stock (CUSIP 75629V104), representing 5.6% of the class. The company disclosed zero sole voting power and zero sole dispositive power. Shared voting power was reported as 28,700,743 shares, while shared dispositive power covered the full 30,001,137 shares. State Street filed as a parent holding company or control person, as indicated under Item 3(g) of the Schedule 13G form.

The filing identified five subsidiaries through which the securities are held, all classified as investment advisers: SSGA Funds Management, Inc.; State Street Global Advisors Europe Limited; State Street Global Advisors Limited; State Street Global Advisors Trust Company; and State Street Global Advisors, Ltd. The filing certifies that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

State Street Corporation disclosed a 5.6% beneficial ownership position, totaling 30,001,137 shares, in Recursion Pharmaceuticals Inc. common stock as of September 30, 2026, held through five investment adviser subsidiaries operating under the State Street Global Advisors umbrella.